Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00398866 · ClinicalTrials.gov registry record · Phase 3
A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb
A Phase 3 study, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT00398866: Completed Phase 3 study, sponsored by Hospital for Special Surgery, New York.
NCT00398866 is a Phase 3 study that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 200 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00398866, a Phase 3 study, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
Hyaluronan is a man-made preparation of a protein complex that occurs naturally in joints and that is often low in people with osteoarthritis. Although hyaluronan has been used in millions of people with knee osteoarthritis, it is not yet FDA approved for use in the thumb. The purpose of this study is to determine the safety and effectiveness of hyaluronan in relieving arthritis symptoms at the base of the thumb and to compare it to corticosteroids and local anesthetic. The principle hypothesis is that treating osteoarthritis at the carpometacarpophalangeal (CMC) joint with injectable hyaluronan will results in greater pain relief, higher patient satisfaction, and better functional outcomes than treating with placebo injections (local anesthetic) or with corticosteroid injections. Treating CMC osteoarthritis with corticosteroid injections will result in greater pain relief, higher patient satisfaction, and better functional outcomes than treating with placebo injections. Patients with worse pre-treatment function will have less improvement and worse post-treatment results after administration of corticosteroid or hyaluronan.
Primary Outcome
Pain intensity measured on a Visual Analog Scale with scores ranging from 0 to 100, with 100 = severe pain.
Interventions
- DRUG Synvisc (Hylan G-F20; hyaluronan injection)
- DRUG Bupivicaine (local anesthesia injection)
- DRUG Kenalog (triamcinolone; corticosteroid injection)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2006-08 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
What the finished NCT00398866 record still lists
NCT00398866 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 3 interventions - of which Synvisc (Hylan G-F20; hyaluronan injection) is the first listed.
NCT00398866 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00398866 about?
NCT00398866 is a clinical study titled "A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb". Hyaluronan is a man-made preparation of a protein complex that occurs naturally in joints and that is often low in people with osteoarthritis. Although hyaluronan has been used in millions of people with knee osteoarthritis, it is not yet FDA approved for use in the thumb. The purpose of this study ...
What is the current status of trial NCT00398866?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2006-08. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00398866?
The interventions under investigation include: Synvisc (Hylan G-F20; hyaluronan injection) (DRUG), Bupivicaine (local anesthesia injection) (DRUG), Kenalog (triamcinolone; corticosteroid injection) (DRUG).
Who is sponsoring clinical trial NCT00398866?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00398866's enrollment target sits among peer trials
200 1353rd of 2000 higher than 613 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia